ICOS is the first immunologic marker to be identified in patients treated with anti-CTLA-4 ..Melanoma ..Jim Breitfeller

ICOS is the first immunologic marker tobe identified inboth tumor tissues and the peripheral blood of patients treated with anti-CTLA-4

Increased ICOS expression is detected on CD4 and CD8
T cells after treatment with 10 mg/kg/dose of anti–CTLA-4
antibody.

An increased and sustained frequency of CD4+ICOS hi
T cells correlated with improved overall survival.

At 10 mg/kg/dose Ipi, CD8+ICOS hi T cells were detectable in tumor tissues
At 3 mg/kg/dose Ipi, CD8+ICOS hi T cells were undetectable in tumor tissues
untreated patients, CD8+ICOS hi T cells were undetectable in tumor tissues

Preoperative CTLA-4 Blockade- Tolerability and Immune
Monitoring in the Setting of a Presurgical Clinical Trial



Preoperative CTLA-4 Blockade: Tolerability and Immune
Monitoring in the Setting of a Presurgical Clinical Trial


This is why the dose should be at least 10mg/kg not 3mg/kg.

Bristol Myer Squibb, please take note!!!!


“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”

~Charles Darwin~

Take Care,

Jimmy B